Cargando…
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans. Anticoagulant effects of DAB and DABG were...
Autores principales: | Kim, Jong-Min, Noh, Jihyeon, Park, Jin-Woo, Chung, Hyewon, Kim, Kyoung-Ah, Park, Seung Bin, Lee, Jun-Seok, Park, Ji-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875894/ https://www.ncbi.nlm.nih.gov/pubmed/35213990 http://dx.doi.org/10.3390/pharmaceutics14020257 |
Ejemplares similares
-
Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023) -
Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012) -
Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018) -
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
por: Glund, Stephan, et al.
Publicado: (2019) -
The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)